RBC on Viridian (VRDN): 'Compelling THRIVE-2 Data Could Change the Game for Chronic TED & VRDN'; PT Raised
Tweet Send to a Friend
RBC Capital analyst Gregory Renza raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $47.00 (from $44.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
